Next Article in Journal
Comparison and Advanced Antimicrobial Strategies of Silver and Copper Nanodrug-Loaded Glass Ionomer Cement against Dental Caries Microbes
Previous Article in Journal
Antimicrobial Resistance Research Collaborations in Asia: Challenges and Opportunities to Equitable Partnerships
Previous Article in Special Issue
Management of Helicobacter Pylori Infection and Effectiveness Rates in Daily Clinical Practice in Spain: 2010–2019

Treatment of Pediatric Helicobacter pylori Infection

by 1,2 and 2,3,*
Department of Pediatrics, New Taipei Municipal Tu Cheng Hospital, Chang Gung Memorial Hospital, New Taipei City 23656, Taiwan
Division of Gastroenterology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan City 33305, Taiwan
Department of Pediatrics and Liver Research Center, Chang Gung Memorial Hospital, Taoyuan City 33305, Taiwan
Author to whom correspondence should be addressed.
Academic Editor: Mitsushige Sugimoto
Antibiotics 2022, 11(6), 757;
Received: 2 May 2022 / Revised: 29 May 2022 / Accepted: 29 May 2022 / Published: 1 June 2022
(This article belongs to the Special Issue Helicobacter pylori Infection: Therapy Changes and Challenges)
Helicobacter pylori infection can cause gastritis, gastric or duodenal ulcers, mucosa-associated lymphoid tissue lymphoma, gastric cancer, and extra-gastrointestinal manifestations. Ideal treatment should be guided by antibiotic susceptibility testing. However, this is not feasible in many regions, so the treatment generally relies on clinical experience and regional culture sensitivity profiles. We aimed to integrate the treatment of pediatric H. pylori infection through a systematic literature review. Databases including PubMed, Cochrane Library, EMBASE, and Scholar were searched using terms containing (Helicobacter OR Helicobacter pylori OR H. pylori) AND (child OR pediatric) for all relevant manuscripts and guidelines, published from January 2011 to December 2021. The eradication rate for pediatric H. pylori infection was not satisfactory using triple therapy, sequential therapy, concomitant therapy, bismuth-based quadruple therapy, or adjuvant therapy with probiotics as the first-line therapy. Most therapies could not achieve the recommended eradication rate of >90%, which may be attributed to varying regional antibiotic resistance and possible poor children’s compliance. More studies are required to establish a best practice for pediatric H. pylori infection treatment. View Full-Text
Keywords: Helicobacter pylori; child; treatment; antibiotic resistance Helicobacter pylori; child; treatment; antibiotic resistance
Show Figures

Figure 1

MDPI and ACS Style

Lai, H.-H.; Lai, M.-W. Treatment of Pediatric Helicobacter pylori Infection. Antibiotics 2022, 11, 757.

AMA Style

Lai H-H, Lai M-W. Treatment of Pediatric Helicobacter pylori Infection. Antibiotics. 2022; 11(6):757.

Chicago/Turabian Style

Lai, Hung-Hsiang, and Ming-Wei Lai. 2022. "Treatment of Pediatric Helicobacter pylori Infection" Antibiotics 11, no. 6: 757.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop